1
|
Byrne R, Coughlan JJ, Rossello X, Ibanez B. The '10 commandments' for the 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2024; 45:1193-1195. [PMID: 38206306 DOI: 10.1093/eurheartj/ehad863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2024] Open
Affiliation(s)
- Robert Byrne
- Cardiovascular Research Institute, Mater Private Network, Eccles Street 73, Dublin 7 D07 WKW8, Ireland
- School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - J J Coughlan
- Cardiovascular Research Institute, Mater Private Network, Eccles Street 73, Dublin 7 D07 WKW8, Ireland
| | - Xavier Rossello
- Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain
- Cardiology Department, Hospital Universitari Son Espases, Palma, Spain
- Faculty of Medicine, Universitat de les Illes Balears (UIB), Palma, Spain
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), C. de Melchor Fernández Almagro, 3, Fuencarral-El Pardo, 28029 Madrid, Spain
| | - Borja Ibanez
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), C. de Melchor Fernández Almagro, 3, Fuencarral-El Pardo, 28029 Madrid, Spain
- Cardiology Department, IIS-Fundación Jiménez Díaz, Madrid, Spain
- CIBERCV, Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0 28029 Madrid, Spain
| |
Collapse
|
2
|
Ibanez B, Byrne R. ACS encompasses a spectrum-unstable angina, NSTEMI, and STEMI. Eur Heart J Acute Cardiovasc Care 2024; 13:187. [PMID: 38243612 DOI: 10.1093/ehjacc/zuae001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Accepted: 12/29/2023] [Indexed: 01/21/2024]
Affiliation(s)
- Borja Ibanez
- Clinical Research Department, Centro Nacional e Investigaciones Cardiovasculares (CNIC) & Cardiology Department, IIS-Fundación Jiménez Díaz & CIBERCV, Madrid, Spain
| | - Robert Byrne
- Department & Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network, Dublin, Ireland
| |
Collapse
|
3
|
Casey L, Jinih M, MacHale J, Kirby F, O' Neill JO, Byrne R, McCarthy JF. Predictability and durability of mitral valve repair in patients with severe degenerative mitral regurgitation in medium sized centres. Ann R Coll Surg Engl 2023. [PMID: 36622239 DOI: 10.1308/rcsann.2022.0076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
INTRODUCTION Mitral valve repair (MVr) is now the treatment of choice to correct severe degenerative mitral regurgitation (MR). Repair rates vary greatly from centre to centre, and the concept of heart valve centres of excellence has been established. OBJECTIVE The purpose of this study was to see whether large international centre repair rates, and outcomes, are transferrable to medium-sized centres with an interest in mitral repair. METHODS Between 2011 and 2018, a total of 346 patients underwent mitral valve surgery by a single surgeon. Of these, 238 consecutive patients had repairs, or attempted repairs for degenerative MR, and are included in this study. RESULTS The study sample consisted of 71% male patients and had a mean age of 64.4 ± 12.3 years; 66% of the study population had concomitant procedures. The overall repair rate in this cohort is 99%. Mean follow up was 3.7 ± 1.9 years. At 5 years, the freedom from MR ≥ 3+ was 95.9 ± 1.9% and at 7 years 91.1 ± 3.8%. Freedom from reoperation at 5 years was 92.9 ± 3.7%, while the 5 years actuarial survival was 89.1 ± 3.7%. On a multivariate analysis, predischarge echo grade was associated with higher risk of future reoperation (odds ratio (OR) = 21.82, p = 0.05). Only age (OR = 1.3, p = 0.03) was predictive of long-term survival. CONCLUSIONS In specialised medium-sized heart centres, where the surgical team have undergone specialist mitral training, favourable short- and long-term outcomes are achievable with mitral repair rates similar to those from large international centres of excellence. In these heart centres, early surgery should be considered for all patients with severe degenerative MR.
Collapse
Affiliation(s)
- L Casey
- Mater Misericordiae University Hospital, Dublin, Ireland
| | - M Jinih
- Mater Private Hospital, Dublin, Ireland
| | - J MacHale
- Mater Misericordiae University Hospital, Dublin, Ireland
| | - F Kirby
- Blackrock Clinic, Dublin, Ireland
| | - J O O' Neill
- Mater Misericordiae University Hospital, Dublin, Ireland
| | - R Byrne
- Mater Misericordiae University Hospital, Dublin, Ireland
| | - J F McCarthy
- Mater Misericordiae University Hospital, Dublin, Ireland.,Mater Private Hospital, Dublin, Ireland.,Blackrock Clinic, Dublin, Ireland
| |
Collapse
|
4
|
Byrne R, Elzain M, Amosu E, Lim SA, Walsh A, McLaughlin K, McMorrow S, Matthews K, Sweeney G, McCarthy G, Dolan C. 247 QUALITY IMPROVEMENT IN DEMENTIA CARE: STREAMLINING CARE PATHWAYS IN A PSYCHIATRY OF OLD AGE SERVICE. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Dementia is increasingly considered a public health priority worldwide in the context of predicted increased prevalence. In Ireland, there are an estimated 67,000 persons living with dementia and by 2041 it is expected to rise to 145,000 persons. Challenges in dementia care have been highlighted in health services across Europe and the ineffective structure of dementia care with fragmented non-person-centred pathways has been identified.
Methods
An initial review of the existing cognitive impairment diagnostic pathways in our specialised Psychiatry of Old Age (POA) Service was undertaken. This included surveying the multidisciplinary team to identify challenges, clinical chart review and audit of physical examination equipment. Diagnostic pathway was updated based on findings and informed by the developing national ‘Model of Care for Dementia in Ireland’ and best practice.
Results
Review findings included lack of standardisation of memory assessment, delays in accessing neuroimaging and laboratory results, gaps in staff training. A care pathway document was developed detailing requirements for care from the point of referral through to cognitive impairment diagnosis. Staff training was completed to accompany the introduction of standardised dementia assessment scales. Access to laboratory/radiology booking was enhanced. A cognitive remediation group was developed by Occupational Therapy as part of post-diagnostic supports for service users. Preliminary data indicates improvements in satisfaction of those attending the group. Physical examination equipment audit resulted in quality improvements.
Conclusion
We demonstrate that a quality improvement approach can be implemented to enhance assessment, diagnosis and care provided to support diagnosis of cognitive impairment and dementia in POA service. The enhanced diagnostic care pathways will be assessed over time to assess impact on care of service users. Preliminary findings are positive and it is an approach that can be adopted in other services and inform development of national memory service developments.
Collapse
Affiliation(s)
- R Byrne
- Sligo Leitrim Mental Health Service , Sligo, Ireland
| | - M Elzain
- Sligo Leitrim Mental Health Service , Sligo, Ireland
| | - E Amosu
- National University of Ireland Galway , Galway, Ireland
| | - SA Lim
- Sligo Leitrim Mental Health Service , Sligo, Ireland
| | - A Walsh
- Sligo Leitrim Mental Health Service , Sligo, Ireland
| | - K McLaughlin
- Sligo Leitrim Mental Health Service , Sligo, Ireland
| | - S McMorrow
- Sligo Leitrim Mental Health Service , Sligo, Ireland
| | - K Matthews
- Sligo Leitrim Mental Health Service , Sligo, Ireland
| | - G Sweeney
- Sligo Leitrim Mental Health Service , Sligo, Ireland
| | - G McCarthy
- Sligo Leitrim Mental Health Service , Sligo, Ireland
- National University of Ireland Galway , Galway, Ireland
- Sligo Medical Academy , Sligo, Ireland
| | - C Dolan
- Sligo Leitrim Mental Health Service , Sligo, Ireland
| |
Collapse
|
5
|
Rajkumar CA, Bello O, McInerney A, Tilsted HH, Johnson V, Fovino LN, Fitzsimons D, Al-Lamee R, Byrne R. Consenting practices in interventional cardiology: an analysis from the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Consenting practices in interventional cardiology vary across different procedures, operators, centres and nations.
Purpose
In order to define best practice for obtaining informed patient consent, it is first necessary to understand how consenting practice differs.
Methods
An online survey of 20 questions was sent to all members of the European Association of Percutaneous Cardiovascular Interventions, addressing consenting practices in elective and emergency scenarios.
Results
We received 483 responses from 74 countries. The majority of respondents (77%) were European operators. Responses were received from consultant cardiologists (n=370), fellows in training (n=55), allied health professionals (n=36) and others (n=21).
Across all respondents, in elective practice, 427 (88.4%) operators obtain written consent for every procedure, the remainder (9.5%) obtain verbal consent only. Consent is obtained by the consultant or fellow who directly performs the procedure in 56.9% cases. For coronary angiography, pre-emptive consent for possible additional procedures (pressure wire and PCI) is taken by operators in all cases (58.6%), some cases (30.6%) and never (11.0%). Prior to interventional therapies, written information detailing the risk of the procedure is provided in every case by 63.8% of operators, sometimes by 25.1% of operators, and is never provided by 11.0% of operators.
In emergency settings, where patients are conscious and have capacity to consent, 274 (56.7%) of respondents obtain written consent, 155 (33.1%) obtain verbal consent only and 52 (10.8%) stated that a consent process was not required. Where consciousness and capacity are impaired, 218 (45.1%) always, 118 (24.4%) sometimes and 145 (30%) never document a written capacity and best interests' assessment.
When asked to rate the overall quality of consenting practices in their own institution, 279 (57.8%) stated these were “excellent” or “above average”, 165 (34.2%) were “average” and 39 operators described consenting practices in their institution as “below average” or “poor”.
Conclusions
Diversity in consenting practice spans elective and emergency procedures. These results suggest that there is substantial variation in the understanding of the rationale, legal requirement, and perceived best practices for consent. Further work should consider the merits of standardisation of consent processes across Europe.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- C A Rajkumar
- Imperial College London , London , United Kingdom
| | - O Bello
- Imperial College Healthcare NHS Trust , London , United Kingdom
| | - A McInerney
- Hospital Clinico San Carlos , Madrid , Spain
| | - H H Tilsted
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - V Johnson
- University Hospital Giessen and Marburg , Giessen , Germany
| | | | - D Fitzsimons
- Queen's University of Belfast , Belfast , United Kingdom
| | - R Al-Lamee
- Imperial College London , London , United Kingdom
| | - R Byrne
- Royal College of Surgeons in Ireland , Dublin , Ireland
| |
Collapse
|
6
|
Pristipino C, Germonpré P, Toni D, Sievert H, Meier B, D'Ascenzo F, Berti S, Onorato EM, Bedogni F, Mas JL, Scacciatella P, Hildick-Smith D, Gaita F, Kyrle PA, Thomson J, Derumeaux G, Sibbing D, Chessa M, Hornung M, Zamorano J, Dudek D, D'Ascenzo F, Omedè P, Ballocca F, Barbero U, Giordana F, Gili S, Iannaccone M, Akagi T, Anzola G, Carroll J, Dalvi B, Angelis CD, Junbo G, Kasner SE, Michel-Behnke I, Musumeci G, Søndergaard L, Tarantini G, Biondi-Zoccai GGL, Capodanno D, Valgimigli M, Byrne R, Kunadian V. European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. Eur Heart J 2021; 42:1545-1553. [PMID: 33507260 DOI: 10.1093/eurheartj/ehaa1070] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2020] [Revised: 10/07/2020] [Accepted: 11/17/2020] [Indexed: 02/05/2023] Open
Abstract
Patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions but to date only one official position paper related to left circulation thromboembolism has been published. This interdisciplinary paper, prepared with the involvement of eight European scientific societies, reviews the available evidence and proposes a rationale for decision making for other PFO-related clinical conditions. In order to guarantee a strict evidence-based process, we used a modified grading of recommendations, assessment, development, and evaluation (GRADE) methodology. A critical qualitative and quantitative evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk/benefit ratio. The level of evidence and the strength of the position statements were weighed and graded according to predefined scales. Despite being based on limited and observational or low-certainty randomised data, a number of position statements were made to frame PFO management in different clinical settings, along with suggestions for new research avenues. This interdisciplinary position paper, recognising the low or very low certainty of existing evidence, provides the first approach to several PFO-related clinical scenarios beyond left circulation thromboembolism and strongly stresses the need for fresh high-quality evidence on these topics.
Collapse
Affiliation(s)
| | | | - Danilo Toni
- Hospital Policlinico Umberto I, Sapienza University, Rome, Italy
| | - Horst Sievert
- CardioVascular Center Frankfurt (CVC Frankfurt), Frankfurt, Germany.,Anglia Ruskin University, Chelmsford, United Kingdom.,University California San Francisco (UCSF), San Francisco, CA, USA
| | | | - Fabrizio D'Ascenzo
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | | | | | | | - Jean-Louis Mas
- Hôpital Sainte-Anne, Université Paris Descartes, Paris, France
| | | | - David Hildick-Smith
- Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, United Kingdom
| | - Fiorenzo Gaita
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | | | | | | | - Dirk Sibbing
- Privatklinik Lauterbacher Mühle am Ostersee, Iffeldorf and Ludwig-Maximilians-Universität (LMU) München, Munich, Germany
| | - Massimo Chessa
- IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
| | - Marius Hornung
- CardioVascular Center Frankfurt (CVC Frankfurt), Frankfurt, Germany
| | | | - Dariusz Dudek
- Jagiellonian University Medical College, Krakow, Poland.,Maria Cecilia Hospital, GVM Care & Research, Cotignola (RA), Italy
| | | | - Fabrizio D'Ascenzo
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | - Pierluigi Omedè
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | | | | | | | | | | | | | | | | | - John Carroll
- University of Colorado Hospital, Denver, CO, USA
| | | | | | - Ge Junbo
- Shanghai Institute of Cardiovascular Disease, Shanghai, China
| | | | - Ina Michel-Behnke
- University Hospital for Children and Adolescents, Medical University Vienna, Vienna, Austria
| | | | | | | | | | | | | | - Davide Capodanno
- Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele", University of Catania, Catania, Italy
| | | | - Robert Byrne
- RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - Vijay Kunadian
- Newcastle University and Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
| |
Collapse
|
7
|
Hemetsberger R, Gori T, Toelg R, Byrne R, Allali A, El-Mawardy M, Rheude T, Weissner M, Sulimov DS, Robinson DR, Richardt G, Abdel-Wahab M. Optical Coherence Tomography Assessment in Patients Treated With Rotational Atherectomy Versus Modified Balloons: PREPARE-CALC OCT. Circ Cardiovasc Interv 2021; 14:e009819. [PMID: 33641372 DOI: 10.1161/circinterventions.120.009819] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Rayyan Hemetsberger
- Department of Cardiology, Heart Center, Segeberger Kliniken, Bad Segeberg, Germany (R.H., R.T., A.A., G.R.)
| | - Tommaso Gori
- Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz and DZHK Rhein-Main, Germany (T.G., M.W.)
| | - Ralph Toelg
- Department of Cardiology, Heart Center, Segeberger Kliniken, Bad Segeberg, Germany (R.H., R.T., A.A., G.R.)
| | | | - Abdelhakim Allali
- Department of Cardiology, Heart Center, Segeberger Kliniken, Bad Segeberg, Germany (R.H., R.T., A.A., G.R.)
| | - Mohamed El-Mawardy
- Department of Cardiology, Vivantes Wenckebach Hospital, Berlin, Germany (M.E.-M.)
| | - Tobias Rheude
- Deutsches Herzzentrum München, Technische Universität München, Germany (T.R.)
| | - Melissa Weissner
- Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz and DZHK Rhein-Main, Germany (T.G., M.W.)
| | - Dmitriy S Sulimov
- Department of Cardiology, Heart Center Leipzig at University of Leipzig, Germany (D.S.S., M.A.-W.)
| | - Derek R Robinson
- Department of Mathematics, University of Sussex, Brighton, United Kingdom (D.R.R.)
| | - Gert Richardt
- Department of Cardiology, Heart Center, Segeberger Kliniken, Bad Segeberg, Germany (R.H., R.T., A.A., G.R.)
| | - Mohamed Abdel-Wahab
- Department of Cardiology, Heart Center Leipzig at University of Leipzig, Germany (D.S.S., M.A.-W.)
| |
Collapse
|
8
|
Jansen E, Russell CG, Appleton J, Byrne R, Daniels LA, Fowler C, Rossiter C, Mallan KM. The Feeding Practices and Structure Questionnaire: development and validation of age appropriate versions for infants and toddlers. Int J Behav Nutr Phys Act 2021; 18:13. [PMID: 33468156 PMCID: PMC7814443 DOI: 10.1186/s12966-021-01079-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 01/05/2021] [Indexed: 01/22/2023] Open
Abstract
Background In order to measure and understand trajectories of parental feeding practices and their relationship with child eating and weight, it is desirable to perform assessment from infancy and across time, in age-appropriate ways. While many feeding practices questionnaires exist, none is presently available that enables tracking of feeding practices from infancy through childhood. The aim of the study was to develop a version of the Feeding Practices and Structure Questionnaire (FPSQ) for parents with infants and toddlers (< 2 years) to be used in conjunction with the original FPSQ for older children (≥2 years) to measure feeding practices related to non-responsiveness and structure across childhood. Methods Constructs and items for the FPSQ for infants and toddlers were derived from the existing and validated FPSQ for older children and supplemented by a review of the literature on infant feeding questionnaires. Following expert review, two versions of the questionnaire were developed, one for milk feeding parents and one for solid feeding parents. Data from two studies were combined (child ages 0–24 months) to test the derived constructs with Confirmatory Factor Analysis for the milk feeding (N = 731) and solid feeding (N = 611) versions. Results The milk feeding version consisted of four factors (18 items) and showed acceptable model fit and good internal reliability: ‘feeding on demand vs. feeding routine’ (α = 0.87), ‘using food to calm’ (α = 0.87), ‘persuasive feeding’ (α = 0.71), ‘parent-led feeding’ (α = 0.79). The same four factors showed acceptable model fit for the solid feeding version (21 items), likewise with good internal reliability (α = 0.74, 0.86, 0.85, 0.84 respectively). Two additional factors (13 items) were developed for the solid feeding version that appeared developmentally appropriate only for children aged 12 months or older: ‘family meal environment’ (α = 0.81) and ‘using (non-)food rewards’ (α = 0.92). The majority of factor-factor correlations were in line with those of the original FPSQ. Conclusions The FPSQ milk and solid feeding versions are the first measures specifically developed as precursors to the FPSQ to measure parental feeding practices in children < 2 years, particularly practices related to non-responsiveness and structure. Further validation in more diverse samples is required. Supplementary Information The online version contains supplementary material available at 10.1186/s12966-021-01079-x.
Collapse
Affiliation(s)
- E Jansen
- School of Exercise and Nutrition Sciences, Queensland University of Technology, Victoria Park Rd, Kelvin Grove, QLD, 4059, Australia. .,Division of Child & Adolescent Psychiatry, Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
| | - C G Russell
- CASS Food Research Centre, Faculty of Health, School of Exercise and Nutrition Sciences, Deakin University, 1 Gheringhap St, Geelong, VIC, 3220, Australia
| | - J Appleton
- Susan Wakil School of Nursing and Midwifery, University of Sydney, 88 Mallett St, Camperdown, NSW, 2050, Australia.,Tresillian Family Care Centres, McKenzie Street, Belmore, Sydney, NSW, 2192, Australia
| | - R Byrne
- School of Exercise and Nutrition Sciences, Queensland University of Technology, Victoria Park Rd, Kelvin Grove, QLD, 4059, Australia.,Institute of Health and Biomedical Innovation, Centre for Children's Health Research, Queensland University of Technology, 62 Graham St, South Brisbane, QLD, 4101, Australia
| | - L A Daniels
- School of Exercise and Nutrition Sciences, Queensland University of Technology, Victoria Park Rd, Kelvin Grove, QLD, 4059, Australia
| | - C Fowler
- Tresillian Family Care Centres, McKenzie Street, Belmore, Sydney, NSW, 2192, Australia.,School of Nursing and Midwifery, Faculty of Health, University of Technology Sydney, 15 Broadway, Ultimo, NSW, 2007, Australia
| | - C Rossiter
- School of Nursing and Midwifery, Faculty of Health, University of Technology Sydney, 15 Broadway, Ultimo, NSW, 2007, Australia
| | - K M Mallan
- School of Behavioural and Health Sciences, Australian Catholic University, 1100 Nudgee Rd, Banyo, QLD, 4014, Australia
| |
Collapse
|
9
|
Patel G, Davis C, Liu Y, Ip K, Debideen KE, Anderson S, Byrne R, Herr D, Rhoads MM, Caputo R, Banov D, Bassani AS. Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design. Int J Pharm Compd 2021; 25:73-81. [PMID: 33503012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Trimix is a widely prescribed penile injection for patients with erectile dysfunction and is only available as a compounded medication. The instability of alprostadil, one of the major ingredients of Trimix, has been a limiting factor in its utilization. There are published stability data for Trimix formulations that have been used to establish a beyond-use-date. However, a robust bracketed study that is shown to be reproducible is highly desirable and meaningful. The purpose of this study was to test the reproducibility of a bracketed stability study when the preparations were made by two different entities to provide beyond-use date information of Trimix preparations that cover a wide range of strengths. A validated stability indicating method was used to compare the stability of a bracketed Trimix - alprostadil 5 µg/mL to 45 µg/mL, papaverine 15 mg/mL to 30 mg/mL, and phentolamine 0.4 mg/mL to 5 mg/mL, and a single-strength preparation containing alprostadil 30 µg/mL, papaverine 30 mg/mL, and phentolamine 2 mg/mL that were compounded and stored following the same methods and conditions, but at two different practice settings. Beyond-use dates of 60 days and 64 days at cold temperature were obtained for the two preparations from two different settings. The consistent results confirmed the reproducibility of the bracketing designs used to determine the beyond-use dates of Trimix. The clinical value of these results stems from the availability of accurate and widely applicable stability data that can be referenced to establish beyond use dates of a number of Trimix preparations with various strength combinations.
Collapse
Affiliation(s)
- Gopesh Patel
- VLS Pharmacy & New Drug Loft, Brooklyn, New York
| | | | - Yi Liu
- Professional Compounding Centers of America, Houston, Texas.
| | - Kendice Ip
- Professional Compounding Centers of America, Houston, Texas
| | | | | | | | - Dylan Herr
- Eagle Analytical Services, Houston, Texas
| | | | | | - Daniel Banov
- Professional Compounding Centers of America, Houston, Texas
| | | |
Collapse
|
10
|
Byrne R, Curley S, Ahmed K, Ahmed M, Gibney J, Mcgillicuddy F. HDL efflux capacity, and particle remodelling in patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Atherosclerosis 2020. [DOI: 10.1016/j.atherosclerosis.2020.10.202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Stefanini GG, Alfonso F, Barbato E, Byrne R, Capodanno D, Colleran R, Escaned J, Giacoppo D, Kunadian V, Lansky A, Mehilli J, Neumann FJ, Regazzoli D, Sanz-Sanchez J, Wijns W, Baumbach A. Management of myocardial revascularisation failure: an expert consensus document of the EAPCI. EUROINTERVENTION 2020; 16:e875-e890. [DOI: 10.4244/eij-d-20-00487] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
12
|
Speed V, Patel RK, Byrne R, Roberts LN, Arya R. A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic. Thromb Res 2020; 192:73-74. [PMID: 32425265 PMCID: PMC7229971 DOI: 10.1016/j.thromres.2020.05.024] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Revised: 05/13/2020] [Accepted: 05/15/2020] [Indexed: 12/15/2022]
Affiliation(s)
- V Speed
- King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK; Institute of Pharmaceutical Sciences, King's College London, London, UK.
| | - R K Patel
- King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK
| | - R Byrne
- King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK; Institute of Pharmaceutical Sciences, King's College London, London, UK
| | - L N Roberts
- King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK
| | - R Arya
- King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK
| |
Collapse
|
13
|
Scheller B, Vukadinovic D, Jeger R, Rissanen TT, Scholz SS, Byrne R, Kleber FX, Latib A, Clever YP, Ewen S, Böhm M, Yang Y, Lansky A, Mahfoud F. Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. J Am Coll Cardiol 2020; 75:1017-1028. [DOI: 10.1016/j.jacc.2019.11.065] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Revised: 11/14/2019] [Accepted: 11/24/2019] [Indexed: 10/24/2022]
|
14
|
Ueki Y, Räber L, Otsuka T, Rai H, Losdat S, Windecker S, Garcia-Garcia HM, Landmesser U, Koolen J, Byrne R, Haude M, Joner M. Mechanism of Drug-Eluting Absorbable Metal Scaffold Restenosis. Circ Cardiovasc Interv 2020; 13:e008657. [DOI: 10.1161/circinterventions.119.008657] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
The pathomechanisms underlying restenosis of the bioabsorbable sirolimus-eluting metallic scaffold (Magmaris) remain unknown. Using serial optical coherence tomography, we investigated causes of restenosis, including the contribution of late scaffold recoil versus neointimal hyperplasia.
Methods:
Patients enrolled in BIOSOLVE-II undergoing serial angiography and optical coherence tomography (post-intervention and follow-up: 6 months and/or 1 year) were analyzed. Patients were divided into 2 groups according to angiographic in-scaffold late lumen loss (LLL) <0.5 or ≥0.5 mm. End points were late absolute scaffold recoil and neointimal hyperplasia area as assessed by optical coherence tomography.
Results:
Serial data were available for analysis from 70 patients (LLL <0.5 mm: n=41; LLL ≥0.5 mm: n=29). Patient and lesion characteristics were comparable, and there was no significant difference in mean and minimal scaffold area between groups at post-intervention. Late absolute scaffold recoil was less among patients with LLL <0.5 mm (0.53±0.68 mm
2
) compared with those with LLL ≥0.5 mm (1.48±1.20 mm
2
;
P
<0.001). Neointimal hyperplasia area was smaller among patients with LLL <0.5 mm at follow-up (1.47±0.33 mm
2
) compared with patients with LLL ≥0.5 mm (1.68±0.34 mm
2
;
P
=0.013). In a matched-frame analysis (post-intervention and follow-up), late absolute scaffold recoil varied according to the underlying plaque type (lipid: 0.63±1.23 mm
2
; calcified: 0.81±1.44 mm
2
; and fibrous: 1.20±1.52 mm
2
;
P
<0.001), while there was no difference with regards to neointimal hyperplasia area (
P
=0.132).
Conclusions:
In addition to neointimal hyperplasia, late scaffold recoil contributed significantly to LLL of sirolimus-eluting absorbable metal scaffolds. The extent of late scaffold recoil was dependent on the underlying plaque morphology and was the highest among fibrotic lesions.
Registration:
URL:
https://www.clinicaltrials.gov
. Unique identifier: NCT01960504.
Collapse
Affiliation(s)
- Yasushi Ueki
- Department of Cardiology, Bern University Hospital, Switzerland (Y.U., L.R., T.O., S.W.)
| | - Lorenz Räber
- Department of Cardiology, Bern University Hospital, Switzerland (Y.U., L.R., T.O., S.W.)
| | - Tatsuhiko Otsuka
- Department of Cardiology, Bern University Hospital, Switzerland (Y.U., L.R., T.O., S.W.)
| | - Himanshu Rai
- Deutsches Herzzentrum München, Technische Universität München, Germany (H.R., R.B., M.J.)
| | - Sylvain Losdat
- Institute of Social and Preventive Medicine and Clinical Trials Unit, University of Bern, Switzerland (S.L.)
| | - Stephan Windecker
- Department of Cardiology, Bern University Hospital, Switzerland (Y.U., L.R., T.O., S.W.)
| | | | - Ulf Landmesser
- Department of Cardiology, Charite Universitätsmedizin Berlin, Germany (U.L.)
| | - Jacques Koolen
- Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands (J.K.)
| | - Robert Byrne
- Deutsches Herzzentrum München, Technische Universität München, Germany (H.R., R.B., M.J.)
| | - Michael Haude
- Medical Clinic I, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Germany (M.H.)
| | - Michael Joner
- Deutsches Herzzentrum München, Technische Universität München, Germany (H.R., R.B., M.J.)
| |
Collapse
|
15
|
Fino R, Byrne R, Softley CA, Sattler M, Schneider G, Popowicz GM. Introducing the CSP Analyzer: A novel Machine Learning-based application for automated analysis of two-dimensional NMR spectra in NMR fragment-based screening. Comput Struct Biotechnol J 2020; 18:603-611. [PMID: 32257044 PMCID: PMC7096735 DOI: 10.1016/j.csbj.2020.02.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Revised: 02/14/2020] [Accepted: 02/22/2020] [Indexed: 11/25/2022] Open
Abstract
NMR-based screening, especially fragment-based drug discovery is a valuable approach in early-stage drug discovery. Monitoring fragment-binding in protein-detected 2D NMR experiments requires analysis of hundreds of spectra to detect chemical shift perturbations (CSPs) in the presence of ligands screened. Computational tools are available that simplify the tracking of CSPs in 2D NMR spectra. However, to the best of our knowledge, an efficient automated tool for the assessment and binning of multiple spectra for ligand binding has not yet been described. We present a novel and fast approach for analysis of multiple 2D HSQC spectra based on machine-learning-driven statistical discrimination. The CSP Analyzer features a C# frontend interfaced to a Python ML classifier. The software allows rapid evaluation of 2D screening data from large number of spectra, reducing user-introduced bias in the evaluation. The CSP Analyzer software package is available on GitHub https://github.com/rubbs14/CSP-Analyzer/releases/tag/v1.0 under the GPL license 3.0 and is free to use for academic and commercial uses.
Collapse
Affiliation(s)
- R Fino
- Institute of Structural Biology, Helmholtz Zentrum München, Neuherberg, Germany.,Biomolecular NMR, Bayerisches NMR Zentrum and Center for Integrated Protein Science Munich at Chemistry Department, Technical University of Munich, Garching, Germany
| | - R Byrne
- Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH), Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland
| | - C A Softley
- Institute of Structural Biology, Helmholtz Zentrum München, Neuherberg, Germany.,Biomolecular NMR, Bayerisches NMR Zentrum and Center for Integrated Protein Science Munich at Chemistry Department, Technical University of Munich, Garching, Germany
| | - M Sattler
- Institute of Structural Biology, Helmholtz Zentrum München, Neuherberg, Germany.,Biomolecular NMR, Bayerisches NMR Zentrum and Center for Integrated Protein Science Munich at Chemistry Department, Technical University of Munich, Garching, Germany
| | - G Schneider
- Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH), Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland
| | - G M Popowicz
- Institute of Structural Biology, Helmholtz Zentrum München, Neuherberg, Germany.,Biomolecular NMR, Bayerisches NMR Zentrum and Center for Integrated Protein Science Munich at Chemistry Department, Technical University of Munich, Garching, Germany
| |
Collapse
|
16
|
Stefanini GG, Naci H, Cao D, Malanchini G, Sturla M, Byrne R, Baber U, Reimers B, Condorelli G, Mossialos E, Windecker S, Mehran R. P6138Quality of clinical trial evidence on devices and drugs approved to treat coronary artery disease. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Regulatory approval of drugs and devices follow two different pathways. Whether different approval pathways underlie meaningful differences in quality of clinical trial evidence is unknown. We aimed to compare the quality of evidence of clinical trials that served as a basis for approval by the U.S. Food and Drug Administration (FDA) of drugs and devices used for the treatment of coronary artery disease.
Methods
FDA databases were searched for devices (i.e., coronary artery drug-eluting stents) and drugs (i.e., agents targeting atherothrombosis) approved between January 1st, 2001 and December 31st, 2017. FDA medical reviews were screened to identify trials that served for approval purposes. The pre-specified primary outcome was the prevalence of randomized trials used for approval (i.e. number of randomized trials/overall number of trials).
Results
A total of 97 trials were identified, 39 serving for approval of 13 devices and 58 serving for approval of 8 drugs. Devices were evaluated by fewer trials per item as compared with drugs (3.0±1.4 vs. 7.3±5.3, P=0.012) with similar study size (501 [100–1314] vs. 379 [183–904] patients per trial, P=0.55). Trials evaluating devices were less frequently randomized (56.4% vs. 94.8%, P<0.001) and more frequently designed powered for clinical endpoints (53.8% vs. 17.2%, P<0.001) as compared to those evaluating drugs. Use of randomization declined over time among trials supporting FDA approval of devices. In addition, significant differences were present between trials evaluating devices and those evaluating drugs in terms of study design, comparator used, blinding to treatment allocation, primary hypothesis, primary endpoint, and type of patients included.
Use of randomized trials for approval
Conclusions
There are substantial differences in clinical trial evidence serving for FDA approval of devices and drugs used for treatment of coronary artery disease. The lower degree of randomized evidence used for approval of devices as compared to drugs raises some concerns, particularly in view of its decline over time.
Collapse
Affiliation(s)
| | - H Naci
- London School of Economics and Political Science, LSE Health, Department of Health Policy, London, United Kingdom
| | - D Cao
- Humanitas University, Milan, Italy
| | | | - M Sturla
- Humanitas University, Milan, Italy
| | - R Byrne
- Deutsches Herzzentrum Muenchen Technical University of Munich, Munich, Germany
| | - U Baber
- Mount Sinai School of Medicine, New York, United States of America
| | - B Reimers
- Humanitas Clinical and Research Center - IRCCS, Milan, Italy
| | | | - E Mossialos
- London School of Economics and Political Science, LSE Health, Department of Health Policy, London, United Kingdom
| | - S Windecker
- Bern University Hospital, Department of Cardiology, Bern, Switzerland
| | - R Mehran
- Mount Sinai School of Medicine, New York, United States of America
| |
Collapse
|
17
|
Allali A, Abdel-Wahab M, Traboulsi H, Hemetsberger R, Byrne R, Geist V, El-Mawardy M, Sulimov D, Neumann FJ, Toelg R, Richardt G. TCT-244 Impact of Different Methods of Lesion Preparation on Side Branches in Calcified Coronary Bifurcations: A Subanalysis of the Randomized PREPARE-CALC Trial. J Am Coll Cardiol 2019. [DOI: 10.1016/j.jacc.2019.08.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Ueki Y, Raber L, Otsuka T, Losdat S, Windecker S, Garcia-Garcia H, Byrne R, Landmesser U, Koolen J, Waksman R, Haude M, Joner M. 122Mechanism and impact of lesion morphology on the late lumen loss of drug-eluting resorbable magnesium scaffolds: a serial optical coherence tomography study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Resorbable Magnesium Scaffolds have demonstrated favourable clinical results with acceptable late lumen loss (LLL). However, the pathomechanisms influencing LLL of resorbable sirolimus-eluting metallic scaffold (Magmaris) have not been analyzed.
Purpose
Using serial optical coherence tomography (OCT), we investigated potential factors, i.e. the contribution of recoil versus neointimal hyperplasia (NIH).
Methods
Patients who were enrolled into BIOSOLVE-II, and underwent serial angiography and OCT (baseline and follow-up: 6-month and/or 1-year) were analyzed. Patients were divided into 2 groups based on angiographic in-scaffold LLL <0.5mm or ≥0.5mm. Endpoints were late absolute recoil and NIH area as assessed by OCT.
Results
A total of 70 patients (LLL <0.5mm: n=41, LLL ≥0.5mm: n=29) were serially analyzed. Patient and lesion characteristics were comparable and there was no significant difference in mean and minimal scaffold area between groups at baseline. Late absolute recoil was significantly smaller among patients with LLL <0.5mm (0.53±0.68 mm2) compared with those with LLL ≥0.5mm (1.48±1.20 mm2, P<0.001) (Figure). A small difference in NIH area at follow-up was observed (LLL <0.5mm: 1.47±0.33 mm2 vs. LLL ≥0.5mm: 1.68±0.34 mm2, P=0.013). In a matched-frame analysis (baseline and follow-up), late absolute recoil varied according to the underlying plaque type (lipid: 0.63±1.23 mm2, calcified: 0.81±1.44 mm2, and fibrous: 1.20±1.52 mm2, P<0.001), while there was no difference with regards to NIH area (P=0.132).
Conclusion
The main driver of late lumen loss of sirolimus-eluting absorbable metal scaffold was late scaffold recoil, while the contribution of NIH was modest. The degree of late scaffold recoil depended on the underlying plaque type and was highest among fibrotic lesions. Future studies will address the impact of procedural factors such as adequate lesion preparation and post-dilatation.
Acknowledgement/Funding
Biotronik
Collapse
Affiliation(s)
- Y Ueki
- Preventive Cardiology & Sports Medicine, Inselspital Bern, Bern, Switzerland
| | - L Raber
- Preventive Cardiology & Sports Medicine, Inselspital Bern, Bern, Switzerland
| | - T Otsuka
- Preventive Cardiology & Sports Medicine, Inselspital Bern, Bern, Switzerland
| | - S Losdat
- University of Bern, Institute of Social and Preventive Medicine and Clinical Trials Unit, Bern, Switzerland
| | - S Windecker
- Preventive Cardiology & Sports Medicine, Inselspital Bern, Bern, Switzerland
| | - H Garcia-Garcia
- Medstar Research Institute, Section of Interventional Cardiology, Washington, United States of America
| | - R Byrne
- German Heart Center of Munich, Munich, Germany
| | | | - J Koolen
- Catharina Hospital, Department of Cardiology, Eindhoven, Netherlands (The)
| | - R Waksman
- Medstar Research Institute, Section of Interventional Cardiology, Washington, United States of America
| | - M Haude
- Lukas Hospital GmbH, Neuss, Germany
| | - M Joner
- German Heart Center of Munich, Munich, Germany
| |
Collapse
|
19
|
Rai H, Alfonso F, Maeng M, Bradaric C, Wiebe J, Christiansen E, Harzer F, Cassese S, Colleran R, Schneider S, Laugwitz KL, Kastrati A, Byrne R. TCT-180 Neointimal Tissue Coverage and Characterization Assessment Using Optical Coherence Tomography Surveillance 6 Months After Implantation of Bioresorbable Scaffolds Versus Conventional Everolimus-Eluting Stents in ISAR-Absorb MI Trial. J Am Coll Cardiol 2019. [DOI: 10.1016/j.jacc.2019.08.237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
20
|
Abdel-Wahab M, Allali A, Byrne R, Geist V, El-Mawardy M, Sulimov D, Neumann FJ, Toelg R, Richardt G. TCT-26 Predictors of Bailout Rotational Atherectomy in Patients With Complex Calcified Coronary Artery Disease: A Pooled Analysis From the Randomized ROTAXUS and PREPARE-CALC Trials. J Am Coll Cardiol 2019. [DOI: 10.1016/j.jacc.2019.08.053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Wiebe J, Schneider S, Cassese S, Rai H, Hoppmann P, Colleran R, Alfonso F, Maeng M, Kretov E, Joner M, Laugwitz KL, Kastrati A, Byrne R. TCT-11 Everolimus-Eluting Bioresorbable Scaffolds Versus Drug-Eluting Stents in Patients With Acute Myocardial Infarction: 2-Year Results of the Randomized ISAR-Absorb MI Trial. J Am Coll Cardiol 2019. [DOI: 10.1016/j.jacc.2019.08.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Curley S, Dillon E, Byrne R, McGillicuddy F. The Hdl Proteome - Challenges To Analysing Hdl-Associated Proteins And Disentangling Associated Proteins From Contaminating Proteins. Atherosclerosis 2019. [DOI: 10.1016/j.atherosclerosis.2019.06.692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Boswell N, Byrne R, Davies PSW. An examination of children's eating behaviours as mediators of the relationship between parents' feeding practices and early childhood body mass index z-scores. Obes Sci Pract 2019; 5:168-176. [PMID: 31019734 PMCID: PMC6469333 DOI: 10.1002/osp4.320] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Revised: 11/24/2018] [Accepted: 11/26/2018] [Indexed: 01/08/2023] Open
Abstract
OBJECTIVE Parent's use of restrictive feeding practices is associated with child weight. Similarly, the literature shows that children's eating behaviours are also associated with child weight. Given this interrelationship between children's eating behaviours, restrictive feeding practices and child weight, examination of possible mediator relationships is warranted. This study aimed to examine the relationships between overt restriction and covert restriction with child body mass index z-scores (BMIz) and determine if children's eating behaviours (satiety responsiveness and food responsiveness) act as mediators. METHOD Parents of Australian children (n = 977) 2.0-5.0 years of age (49.4% male) provided data in an online survey on child eating behaviours, parent's restrictive feeding practices and child anthropometrics (modified z-scores were created to screen for biologically implausible values). Correlation analysis was used to determine variables to include in mediation models. Hayes' PROCESS macros in spss was used to examine mediation, controlling for covariates of child BMIz. RESULTS Overt restriction was the only parent feeding practice related to child BMIz (B = 0.132, P = 0.04). Mediation analysis showed that the indirect effect of overt restriction on child BMIz (controlling for child age, gender, parent BMI and income) became non-significant when controlling for food responsiveness, thus suggesting full mediation, explaining 5.75% of the relation. CONCLUSION Overt restriction and covert restriction have distinctly different relationships with children's eating behaviours. Food responsiveness appears an important intermediary in the relationship between overt restriction and child BMIz.
Collapse
Affiliation(s)
- N. Boswell
- The University of QueenslandBrisbaneQLDAustralia
| | - R. Byrne
- Queensland University of TechnologyBrisbaneQLDAustralia
| | | |
Collapse
|
24
|
Hernandez G, Lemor A, Clark D, Blumer V, Byrne R, Fowler R, Sandhaus E, Weingarten A, Frischhertz B, Schlendorf K, Zalawadiya S, Lindenfeld J, Menachem J. In Hospital Outcomes in Adult Congenital Heart Disease Patients with Fontan Undergoing Heart Transplantation - A Decade Nationwide Analysis from 2004 until 2014. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.257] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
25
|
Pristipino C, Sievert H, D’Ascenzo F, Louis Mas J, Meier B, Scacciatella P, Hildick-Smith D, Gaita F, Toni D, Kyrle P, Thomson J, Derumeaux G, Onorato E, Sibbing D, Germonpré P, Berti S, Chessa M, Bedogni F, Dudek D, Hornung M, Zamorano J, D’Ascenzo F, Omedè P, Ballocca F, Barbero U, Giordana F, Gili S, Iannaccone M, Capodanno D, Valgimigli M, Byrne R, Akagi T, Carroll J, Dalvi B, Ge J, Kasner S, Michel-Behnke I, Pedra C, Rhodes J, Søndergaard L, Thomassen L, Biondi-Zoccai GGL. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J 2018; 40:3182-3195. [PMID: 30358849 DOI: 10.1093/eurheartj/ehy649] [Citation(s) in RCA: 165] [Impact Index Per Article: 27.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Accepted: 09/28/2018] [Indexed: 02/05/2023] Open
Abstract
Abstract
The presence of a patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions; however, the subject remains controversial and no official statements have been published. This interdisciplinary paper, prepared with involvement of eight European scientific societies, aims to review the available trial evidence and to define the principles needed to guide decision making in patients with PFO. In order to guarantee a strict process, position statements were developed with the use of a modified grading of recommendations assessment, development, and evaluation (GRADE) methodology. A critical qualitative and quantitative evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk/benefit ratio. The level of evidence and the strength of the position statements of particular management options were weighed and graded according to predefined scales. Despite being based often on limited and non-randomised data, while waiting for more conclusive evidence, it was possible to conclude on a number of position statements regarding a rational general approach to PFO management and to specific considerations regarding left circulation thromboembolism. For some therapeutic aspects, it was possible to express stricter position statements based on randomised trials. This position paper provides the first largely shared, interdisciplinary approach for a rational PFO management based on the best available evidence.
Collapse
Affiliation(s)
| | - Horst Sievert
- CardioVascular Center (CVC) Frankfurt, Frankfurt, Germany
- Anglia Ruskin University, Chelmsford, United Kingdom, and University of California San Francisco (UCSF), San Francisco, USA
| | - Fabrizio D’Ascenzo
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | - Jean Louis Mas
- Hôpital Sainte-Anne, Université Paris Descartes, Paris, France
| | | | - Paolo Scacciatella
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | - David Hildick-Smith
- Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, United Kingdom
| | - Fiorenzo Gaita
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | - Danilo Toni
- Hospital Policlinico Umberto I, Sapienza University, Rome, Italy
| | | | | | | | | | - Dirk Sibbing
- Campus Großhadern, Ludwig-Maximilians-Universität (LMU), Munich, Germany
| | | | | | - Massimo Chessa
- Policlinico, San Donato, University Hospital, San Donato Milanese, Milan, Italy
| | - Francesco Bedogni
- Policlinico, San Donato, University Hospital, San Donato Milanese, Milan, Italy
| | | | - Marius Hornung
- CardioVascular Center (CVC) Frankfurt, Frankfurt, Germany
| | | | - Fabrizio D’Ascenzo
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | - Pierluigi Omedè
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | - Flavia Ballocca
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | - Umberto Barbero
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | - Francesca Giordana
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | - Sebastiano Gili
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | - Mario Iannaccone
- Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
| | - Davide Capodanno
- Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
| | | | - Robert Byrne
- Deutsches Herzzentrum München, Technische Universität München, Munich, Germany
| | | | - John Carroll
- University of Colorado Hospital, Denver, CO, USA
| | | | - Junbo Ge
- Shanghai Institute of Cardiovascular Disease, Shanghai, China
| | - Scott Kasner
- University of Pennsylvania, Philadelphia, PA, USA
| | | | - Carlos Pedra
- Dante Pazzanese Instituto de Cardiologia, Sao Paulo, Brazil
| | - John Rhodes
- Nicklaus Children’s Hospital, Miami, USA, FL
| | | | | | - Giuseppe G L Biondi-Zoccai
- Sapienza University of Rome, Latina, Italy
- Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy
| | | | | | | | | |
Collapse
|
26
|
Carey I, Byrne R, Childs K, Horner M, Bruce M, Wang B, Dusheiko G, Agarwal K. Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B. J Viral Hepat 2018; 25:1139-1150. [PMID: 29660209 DOI: 10.1111/jvh.12916] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Accepted: 03/20/2018] [Indexed: 12/26/2022]
Abstract
Tubular renal toxicity is a side-effect of long-term therapy with nucleos(t)ide analogue(s) (NA) in chronic hepatitis B (CHB). There are no established surrogate markers in plasma of early NA-related toxicity. Neutrophil gelatinase-associated lipocalin (NGAL) is a protein produced by tubular cells following renal damage. We aimed therefore to retrospectively compare conventional renal markers (estimated glomerular filtration rates (eGFR) and urinary protein/creatinine ratio uPCR) with a sensitive biomarker (NGAL) in CHB patients on long-term NA therapy and assess the ability of new markers to predict NA-related renal toxicity (new onset of nonalbumin proteinuria). A total of 192 naïve CHB patients (median age 41 years, 78% males, 25% HBeAg+, 35% cirrhosis) were NA treated for at least 5 years (median 8.34 years, range 5.54-11.1 years). The eGFR and uPCR were compared at baseline and last clinical visit with serum NGAL concentrations measured by ELISA at same time-points and assessed according to the presence/absence of nonalbumin proteinuria at last visit. While baseline and last visit eGFR were similar (median:78 vs 84 mL/min), serum NGAL concentrations increased during therapy (median:9.4 vs 16.4 ng/mL, P < .05). The proportion of patients with proteinuria (uPCR > 15) increased between baseline and last visit (4.6% vs 21.4%, P < .05), with 30 (16%) patients having de novo nonalbumin proteinuria at last visit. High baseline NGAL concentrations were exclusive to patients with de novo nonalbumin proteinuria (median:31.7 vs 7.8 ng/mL, P < .01) and baseline NGAL levels >25 mg/mL were predictive of nonalbumin proteinuria at last visit (AUROC = 0.813). In conclusion, serum NGAL can act as a surrogate marker of early renal injury (de novo nonalbumin proteinuria) in CHB on long-term NA therapy.
Collapse
Affiliation(s)
- I Carey
- Institute of Liver Studies, King's College Hospital, London, UK
| | - R Byrne
- Institute of Liver Studies, King's College Hospital, London, UK
| | - K Childs
- Institute of Liver Studies, King's College Hospital, London, UK
| | - M Horner
- Institute of Liver Studies, King's College Hospital, London, UK
| | - M Bruce
- Institute of Liver Studies, King's College Hospital, London, UK
| | - B Wang
- Institute of Liver Studies, King's College Hospital, London, UK
| | - G Dusheiko
- Institute of Liver Studies, King's College Hospital, London, UK
| | - K Agarwal
- Institute of Liver Studies, King's College Hospital, London, UK
| |
Collapse
|
27
|
Giacoppo D, Alfonso F, Xu B, Claessen B, Adriaenssens T, Naber C, Perez-Vizcayno M, Kang DY, Degenhardt R, Pleva L, Baan J, Park DW, Gao R, Park SJ, Henriques JPS, Kastrati A, Byrne R. TCT-228 Outcomes After Treatment of Coronary In-Stent Restenosis With Drug-Coated Balloon Versus Drug-Eluting Stent According to the Presence or Absence of Diabetes Mellitus: A Prespecified Analysis of the DAEDALUS Study. J Am Coll Cardiol 2018. [DOI: 10.1016/j.jacc.2018.08.1352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
28
|
Giacoppo D, Alfonso F, Xu B, Claessen B, Adriaenssens T, Naber C, Perez-Vizcayno MJ, Baan J, Degenhardt R, Pleva L, Fernandez C, Gao R, Henriques JP, Kastrati A, Byrne R. 1463Differential effectiveness of drug-coated balloon vs. drug-eluting stent for bare-metal or drug-eluting stent restenosis: a primary prespecified subanalysis from the DAEDALUS study. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.1463] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - F Alfonso
- University Hospital De La Princesa, Madrid, Spain
| | - B Xu
- Fu Wai Hospital, Beijing, China People's Republic of
| | - B Claessen
- Academic Medical Center, Amsterdam, Netherlands
| | | | - C Naber
- Contilia Heart and Vascular Center, Essen, Germany
| | | | - J Baan
- Academic Medical Center, Amsterdam, Netherlands
| | - R Degenhardt
- Heart and Vascular Center, Rotenburg an der Fulda, Germany
| | - L Pleva
- University Hospital Ostrava, Ostrava, Czech Republic
| | | | - R Gao
- Fu Wai Hospital, Beijing, China People's Republic of
| | | | | | - R Byrne
- German Heart Center, Munich, Germany
| |
Collapse
|
29
|
Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, Halvorsen S, Lau D, Lopez-Cabanillas N, Lettino M, Marin F, Obel I, Rubboli A, Storey RF, Valgimigli M, Huber K, Potpara T, Blomström Lundqvist C, Crijns H, Steffel J, Heidbüchel H, Stankovic G, Airaksinen J, Ten Berg JM, Capodanno D, James S, Bueno H, Morais J, Sibbing D, Rocca B, Hsieh MH, Akoum N, Lockwood DJ, Gomez Flores JR, Jardine R. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace 2018; 21:192-193. [DOI: 10.1093/europace/euy174] [Citation(s) in RCA: 180] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Accepted: 06/28/2018] [Indexed: 02/06/2023] Open
Affiliation(s)
- Gregory Y H Lip
- Institute of Cardiovascular Sciences, University of Birmingham, UK
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK
- Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark
| | - Jean-Phillippe Collet
- Sorbonne Université Paris 6, ACTION Study Group (www.action-coeur.org), Institut de Cardiologie Hôpital Pitié-Salpêtrière (APHP), INSERM UMRS, Paris, France
| | - Michael Haude
- Städtische Kliniken Neuss Lukaskrankenhaus Gmbh Kardiologie, Nephrologie, Pneumologie, Neuss, Germany
| | - Robert Byrne
- Deutsches Herzzentrum Muenchen, Munich, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
| | - Eugene H Chung
- University of North Carolina at Chapel Hill, Medicine, Cardiology, Electrophysiology, Chapel Hill, NC, USA
| | - Laurent Fauchier
- Centre Hospitalier Universitaire Trousseau et Faculté de Médecine—Université François Rabelais, Tours, France
| | - Sigrun Halvorsen
- Department of Cardiology, Oslo University Hospital Ulleval, and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Dennis Lau
- Centre for Heart Rhythm Disorders, South Australian Health and Medical Research Institute, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia
| | | | - Maddalena Lettino
- Cardiology Department, Humanitas Research Hospital, Rozzano, MI, Italy
| | - Francisco Marin
- Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
| | - Israel Obel
- Milpark Hospital, Cardiology Unit, Johannesburg, South Africa
| | - Andrea Rubboli
- Division of Cardiology, Laboratory of Interventional Cardiology, Ospedale Maggiore, Bologna, Italy
| | - Robert F Storey
- Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
| | | | - Kurt Huber
- 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital Vienna, Vienna, Austria
| | - Tatjana Potpara
- School of Medicine, Belgrade University, Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia
| | | | - Harry Crijns
- Cardiology Department, Maastricht UMC+, Maastricht, Netherlands
| | - Jan Steffel
- University Heart Center Zurich, Zurich, Switzerland
| | - Hein Heidbüchel
- Antwerp University and University Hospital, Antwerp, Belgium
| | - Goran Stankovic
- Department of Cardiology, Clinical Center of Serbia, Belgrade, Serbia
| | - Juhani Airaksinen
- Turku University Hospital, Cardiology, Department of Internal Medicine, Turku, Finland
| | | | - Davide Capodanno
- Ferrarotto Hospital, Azienda Ospedaliero-Univ, Policlinico-Vittorio Emanuele, University of Catania, Cardiologia Department, University of Catania, Catania, Italy
| | - Stefan James
- Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Senior Interventional Cardiologist, Uppsala University Hospital, Uppsala, Sweden
| | - Hector Bueno
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernandez Almagro, Madrid, Spain
- Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Joao Morais
- Department of Cardiology, Leiria Hospital Centre, Portugal
| | - Dirk Sibbing
- Oberarzt, Medizinische Klinik und Poliklinik I, Ludwig-Maximilians-Universität (LMU), Campus Großhadern, München, Germany
| | - Bianca Rocca
- Department of Pharmacology, Catholic University School of Medicine, Rome, Italy
| | | | - Nazem Akoum
- Cardiology Department, University of Washington, Seattle, USA
| | | | | | | | | |
Collapse
|
30
|
Morrissey M, Byrne R, Lynam-Lennon N, Butler C, Nulty C, Kennedy S, Dunne M, McCabe N, Reynolds J, O’Sullivan J. PO-388 The gastrointestinal tract tumour microenvironment differentially influences maturation of and cytokine secretion from dendritic cells. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
31
|
Nelson DW, Damluji AA, Patel N, Valgimigli M, Windecker S, Byrne R, Nolan J, Patel T, Brilakis E, Banerjee S, Mayol J, Cantor WJ, Alfonso CE, Rao SV, Moscucci M, Cohen MG. Influence of operator experience and PCI volume on transfemoral access techniques: A collaboration of international cardiovascular societies. Cardiovascular Revascularization Medicine 2018; 19:143-150. [DOI: 10.1016/j.carrev.2017.12.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Revised: 12/21/2017] [Accepted: 12/22/2017] [Indexed: 10/18/2022]
|
32
|
Nelson DW, Damluji A, Patel N, Valgimigli M, Windecker S, Byrne R, Nolan J, Patel T, Brilakis E, Banerjee S, Mayol J, Cantor W, Alfonso C, Rao S, Moscucci M, Cohen M. CRT-200.25 Influence of Operator Experience and PCI Volume on Transfemoral Access Techniques: A Collaboration of International Cardiovascular Societies. JACC Cardiovasc Interv 2018. [DOI: 10.1016/j.jcin.2018.01.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Byrne R, Stefanini G, Capodanno D, Onuma Y, Baumbach A, Escaned J, Haude M, James S, Joner M, Jüni P, Kastrati A, Oktay S, Wijns W, Serruys P, Windecker S. Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. EUROINTERVENTION 2018; 13:1574-1586. [DOI: 10.4244/eij20170912-01] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
34
|
Cassese S, Byrne R, Jüni P, Wykrzykowska J, Puricel S, Ndrepepa G, Schunkert H, Fusaro M, Cook S, Kimura T, Henriques J, Serruys P, Windecker S, Kastrati A. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. EUROINTERVENTION 2018; 13:1565-1573. [DOI: 10.4244/eij-d-17-00492] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
35
|
Byrne R, Lapointe JM, Radke P, Bayer G, Steigerwald K, Wittchow E, Joner M. Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. Thromb Haemost 2017; 105:864-72. [DOI: 10.1160/th10-11-0698] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2010] [Accepted: 01/16/2011] [Indexed: 12/23/2022]
Abstract
SummaryThe advent of drug-eluting balloon (DEB) therapy has represented an important development in interventional cardiology. Nevertheless, pre-clinical data with this technology remain scant, and comparative studies have not previously been published. Bare metal stents were implanted in the coronary arteries of 15 pigs followed by balloon angioplasty. Animals were allocated to treatment with a 60-second inflation of one of four different balloon catheters: a conventional untreated plain angioplasty balloon (PBA, Biotronik AG), the Pantera Lux DEB (3.0 μg/mm2 paclitaxel; BTHC excipient, Biotronik AG), the Elutax DEB (2.0 μg/mm2 paclitaxel; no excipient; Aachen Resonance), or the SeQuent Please DEB (3.0 μg/mm2 paclitaxel; iopromide excipient: B. Braun). Twenty-eight days following balloon deployment, animals underwent repeat angiography for quantitative coronary angiography analysis and euthanasia for histopathologic assessment. By histology, the mean neointimal thickness was 0.44 ± 0.19 mm with PBA, 0.35 ± 0.13 mm with Pantera Lux, 0.61 ± 0.20 mm with Elutax, and 0.47 ± 0.21 mm with SeQuent Please DEB (p=0.02). In comparison with PBA, deployment of the Pantera Lux or the SeQuent Please DEB resulted in delayed healing characterised by significant increases in fibrin, neointimal cell vacuity and delayed re-endothelialisation. In conclusion, investigation of comparative DEB performance in a porcine model of advanced coronary restenosis reveals significant heterogeneity of neointimal suppression between the devices tested with numerically lowest values seen in the Pantera Lux group. On the other hand, evidence of delayed healing was observed in the most effective DEB groups.
Collapse
|
36
|
Byrne R, Hausleiter J, Laugwitz KL, Sibbing D, Orban M. Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock. Thromb Haemost 2017; 106:555-8. [DOI: 10.1160/th11-04-0267] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2011] [Accepted: 06/08/2012] [Indexed: 11/05/2022]
|
37
|
Sibbing D, Sonntag U, Ellert J, Schulz S, Byrne R, Mehilli J, Schömig A, Kastrati A, Sarafoff N. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thromb Haemost 2017; 104:626-32. [DOI: 10.1160/th09-11-0800] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2009] [Accepted: 04/30/2010] [Indexed: 11/05/2022]
Abstract
SummaryClopidogrel is a prodrug that is converted via the hepatic cytochrome P450 system into its active thiol metabolite. Evidence is accumulating that proton pump inhibitors (PPIs) inhibit this enzymatic pathway and may therefore attenuate the antiplatelet effect of clopidogrel. The objective of this study was to investigate whether patients on clopidogrel therapy after drug-eluting stent (DES) placement who also receive a PPI are at higher risk of stent thrombosis (ST). This is a retrospective analysis of patients who received dual antiplatelet treatment including clopidogrel after DES placement. Outcomes were compared according to PPI therapy. The primary endpoint was the incidence of definite ST at 30 days. Secondary endpoints were death, combined death or ST and myocardial infarction (MI). The study population included 3,338 patients and 698 patients (20.9%) received PPIs. Patients receiving a PPI had a higher risk profile at baseline. Multivariate analysis showed that PPI treatment was not independently associated with the occurrence of ST [adjusted HR 1.8 (95% CI: 0.7–4.7), p=0.23] or MI [adjusted HR 1.3 (0.8–2.3), p=0.11]. PPI treatment was significantly associated with death [adjusted HR 2.2 (1.1–4.3), p=0.02] and death or ST [adjusted HR 3.3(1.7–6.7), p=0.02]. Concomitant treatment with a PPI in patients receiving dual antiplatelet treatment after coronary stenting is not an independent predictor of ST. The higher mortality is probably due to confounding as patients on PPIs had a higher risk profile at baseline.
Collapse
|
38
|
Byrne R. ESC Congress 2017 - what did we learn? EUROINTERVENTION 2017; 13:893-895. [PMID: 29051124 DOI: 10.4244/eijv13i8a131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
39
|
Colleran R, Byrne R, Rai H, Voll F, Giacoppo D, Cassese S, Joner M, Schunkert H, Kastrati A. TCT-506 An updated meta-analysis of randomized trials comparing complete versus culprit-only revascularization in patients undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2017. [DOI: 10.1016/j.jacc.2017.09.622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
Colleran R, Harada Y, Kufner S, Giacoppo D, Joner M, Cassese S, Ibrahim T, Laugwitz KL, Kastrati A, Byrne R. Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis. EUROINTERVENTION 2017; 13:962-969. [DOI: 10.4244/eij-d-16-00939] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
41
|
Mylotte D, Byrne R. EuroPCR 2017, late-breaking clinical trials and EuroIntervention. EUROINTERVENTION 2017; 13:e499-e502. [DOI: 10.4244/eijv13i5a77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
42
|
Williams H, Hodgkinson A, Brown A, Byrne R, Burgess V, Hamedi N, Balazs J. P3617Improving the uptake of anticoagulation for prevention of atrial fibrillation related stroke. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
|
44
|
Abstract
Activity‐based probes (ABPs) have been used to dissect the biochemical/structural properties and cellular functions of deubiquitinases. However, their utility in studying cysteine‐based E3 ubiquitin ligases has been limited. In this study, we evaluate the use of ubiquitin‐ABPs (Ub‐VME and Ub‐PA) and a novel set of E2–Ub‐ABPs on a panel of HECT E3 ubiquitin ligases. Our in vitro data show that ubiquitin‐ABPs can label HECT domains. We also provide the first evidence that, in addition to the RBR E3 ubiquitin ligase Parkin, E2–Ub‐ABPs can also label the catalytic HECT domains of NEDD4, UBE3C, and HECTD1. Importantly, the endogenous proteasomal E3 ligase UBE3C was also successfully labelled by Ub‐PA and His‐UBE2D2–Ub‐ABP in lysate of cells grown under basal conditions. Our findings provide novel insights into the use of ABPs for the study of HECT E3 ubiquitin ligases.
Collapse
Affiliation(s)
- Robert Byrne
- Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath, BA2 7AY, UK
| | - Thomas Mund
- MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0QH, UK
| | - Julien D F Licchesi
- Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath, BA2 7AY, UK
| |
Collapse
|
45
|
Colleran R, Joner M, Foin N, Byrne R. Acute myocardial infarction in a young endurance athlete caused by probable plaque erosion. EUROINTERVENTION 2017; 13:e246-e247. [DOI: 10.4244/eij-d-17-00087] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
46
|
Poirier V, Schwartz L, Eddy D, Berman R, Chacour S, Wynne J, Cavanaugh W, Martin D, Byrne R, Sanberg P. Thoughts on Improving Innovation: What Are the Characteristics of Innovation and How Do We Cultivate Them? technol innov 2017. [DOI: 10.21300/18.4.2017.319] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
47
|
Nelson D, Damluji A, Moscucci M, Rao S, Valgimigli M, Windecker S, Byrne R, Cohen F, Patel T, Brilakis E, Banerjee S, Cantor W, Alfonso C, Cohen M. VARIABILITY IN TRANSFEMORAL ACCESS FOR CORONARY ANGIOGRAPHY AND INTERVENTIONS: RESULTS FROM AN INTERNATIONAL SURVEY. J Am Coll Cardiol 2017. [DOI: 10.1016/s0735-1097(17)34761-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
48
|
Ahdash Z, Byrne R, Hopfner KP, Politis A. Dissecting the Mechanism of the HerA NurA DNA Break Resection Complex using Native Mass Spectrometry. Biophys J 2017. [DOI: 10.1016/j.bpj.2016.11.2783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
49
|
Harada Y, Michel J, Koenig W, Rheude T, Colleran R, Giacoppo D, Wiebe J, Kastrati A, Byrne R. TCT-337 Prognostic value of high-sensitivity cardiac troponin T and gender differences in patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2016. [DOI: 10.1016/j.jacc.2016.09.468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
50
|
Wiebe J, Harada Y, Hoppmann P, Colleran R, Kufner S, Cassese S, Xhepa E, Rheude T, Giacoppo D, Ibrahim T, Laugwitz KL, Kastrati A, Byrne R. TCT-399 Impact of post-dilatation on angiographic and clinical outcomes of patients undergoing bioresorbable scaffold implantation in clinical practice. J Am Coll Cardiol 2016. [DOI: 10.1016/j.jacc.2016.09.534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|